

### Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

### Listing of Claims

- 1 – 5. (Canceled)
6. (Withdrawn) An antibody obtained by the method of claim 1.
7. (Withdrawn) A method for producing an antibody with agonistic activity, which comprises the steps of:
  - (a) determining the binding activity of an antibody and selecting an antibody with binding activity;
  - (b) modifying the antibody selected in step (a);
  - (c) determining the agonistic activity of the modified antibody of step (b) and selecting an antibody with agonistic activity;
  - (d) introducing a host cell with a vector carrying a DNA that encodes the antibody selected in step (c); and
  - (e) culturing the host cell of step (d).
8. (Withdrawn) The production method of claim 7, wherein the modified antibody is a minibody.
9. (Withdrawn) The production method of claim 8, wherein the minibody is an sc(Fv)<sub>2</sub>.

10. (Withdrawn) The production method of claim 7, wherein the agonistic activity is not determined prior to antibody modification.

11. (Withdrawn) The production method of claim 7, wherein the antibody is one against a protein expressed on a cell membrane.

12 – 14. (Canceled)

15. (New) A method of screening comprising:

(a) providing a plurality of whole antibodies that bind to a given antigen, wherein the plurality of whole antibodies comprises antibodies with weak or undetectable agonistic activity for the antigen;

(b) producing a minibody of each whole antibody;

(c) screening the minibodies for their ability to agonize the antigen; and

(d) selecting a minibody if it exhibits agonistic activity greater than that of its respective whole antibody.

16. (New) The method of claim 15, wherein the antigen is a protein expressed on a cell membrane.

17. (New) The method of claim 15, wherein the antigen is a receptor.

18. (New) The method of claim 15, wherein the antigen is selected from the group consisting of erythropoietin (EPO) receptors, granulocyte colony-stimulating factor (G-CSF) receptors, insulin receptors, Flt-3 ligand receptors, platelet-derived growth factor (PDGF) receptors, interferon (IFN)- $\alpha$  and - $\beta$  receptors, leptin receptors, growth hormone (GH) receptors, interleukin (IL)-10 receptors, insulin-like growth factor (IGF)-I receptors, leukemia inhibitory factor (LIF) receptors, ciliary neurotrophic factor (CNTF) receptors, HLA-A, HLA-B, HLA-C,

HLA-E, HLA-F, HLA-G, HLA-H, HLA-DR, HLA-DQ, HLA-DP, CD1, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD10, CD11a, CD11b, CD11c, CD13, CD14, CD15s, CD16, CD18, CD19, CD20, CD21, CD23, CD25, CD28, CD29, CD30, CD32, CD33, CD34, CD35, CD38, CD40, CD41a, CD41b, CD42a, CD42b, CD43, CD44, CD45, CD45RO, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD51, CD54, CD55, CD56, CD57, CD58, CD61, CD62E, CD62L, CD62P, CD64, CD69, CD71, CD73, CD95, CD102, CD106, CD122, CD126, and CDw130.

19. (New) The method of claim 15, wherein the antigen is a thrombopoietin (TPO) receptor.

20. (New) The method of claim 15, wherein the antigen is CD47.

21. (New) The method of claim 15, wherein the minibodies are sc(Fv)<sub>2</sub>.

22. (New) The method of claim 15, wherein the minibodies are diabodies.

23. (New) The method of claim 15, wherein the agonistic activities of the whole antibodies are not assayed prior to step (b).

24. (New) The method of claim 15, wherein the plurality of whole antibodies are together in a mixture.